Skip to main content

25 April 2006

Smiths Medical cited for its role as manufacturer

Smiths Medical, part of the global engineering business Smiths Group, today announced that its Cleo 90 insulin infusion set has received a 2006 Medical Design Excellence Award.

Created after extensive conversations with insulin pump users, a team from Smiths Medical redefined the industry standard for infusion sets for individuals who rely on insulin pumps to control their diabetes. These devices are used by people who use an insulin pump, such as Smith Medicals Deltec Cozmo® insulin pump, to manage diabetes. The pump slowly delivers insulin through a small tube inserted in the body with a device such as the Cleo 90 infusion set.

We are honoured to receive this important industry recognition of the Cleo 90 infusion sets unique design and new features that reduce complexity, maximize comfort and ensure safety for persons with diabetes, said Jim Stitt, president of Smiths Medical MD, Inc. The Cleo 90 infusion set is the result of listening to our customers, and asking them what features would make their lives easier. Its no surprise that the Cleo 90 infusion set is getting such positive reviews our customers helped us design it.

Now in its ninth year, the Medical Device Excellence Awards competition is organized and presented by Canon Communications LLC (Los Angeles) and is the only awards program that exclusively recognizes contributions and advances in the design of medical products. Entries are evaluated on the basis of their design and engineering features, including innovative use of materials, user-related functions that improve healthcare delivery and change traditional medical attitudes or practices, features thatprovide enhanced benefits to the patient, and the ability of the product development team to overcome design and engineering challenges so the product meets its clinical objectives.

A comprehensive review of the entries was performed by an impartial, multidisciplinary panel of third-party jurors with expertise in biomedical engineering, human factors, industrial design, medicine, and diagnostics.

The Cleo 90 infusion set is an all-in-one infusion set that includes an integrated sturdy sterile package, easy-to-use insertion device, 360 site connection, and automatic, needle-safe disposal container. The Cleo 90 infusion set can be used with any open system insulin pump. Users follow a simple, three-step procedure: 1) remove the cap (its shaped like a plastic bottle cap); 2) insert the cannula (a hidden needle automatically retracts after a plastic cannula is inserted); and 3) attach tubing to the cannula, which is then connected to an insulin pump. For more information, visit http://www.cleoinfusionsets.com/.

The 2006 Medical Device Excellence Award winners will be honoured at a June 7 ceremony during the Medical Design & Manufacturing (MD&M) East Conference and Exposition in New York Citys Javits Convention Center. 

For information about the Medical Design Excellence Awards, visit the MDEA Web site at http://www.mdeawards.com/.

ENDS

General media enquiries

Contact our global media and communications team at:

Tom Steiner

Tom Steiner

Head of External Communications

+44 (0) 20 7004 1600

Email Arrow right icon
Charlotte Bulmer

Charlotte Bulmer

Corporate Communications Executive

+44 (0) 20 7004 1600

Email Arrow right icon

Please note – the press team can only answer enquiries from accredited members of the press.

Related articles

Jet Propulsion Lab

Smiths Group supports NASA’s Europa Clipper mission to explore Jupiter’s moon, Europa  

Find out more Call to action arrow icon
Smiths Detection Scanner At Airport

Smiths Detection awarded service subcontract

Providing preventative and corrective maintenance for 486 hold baggage scanning systems across 41 airports in the United States

Find out more Call to action arrow icon
Sustainability At Smiths Report 2024

Smiths Group publishes 2024 ‘Sustainability at Smiths’ report

Smiths Group publishes its latest ‘Sustainability at Smiths’ report for the fiscal year 2024. The report outlines the progress that Smiths Group has made during the year on its ESG agenda.

Find out more Call to action arrow icon
Sign up for updates Call to action arrow icon